Carlotta AbbÃ

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4394116/publications.pdf

Version: 2024-02-01

1684188 1474206 13 73 5 9 citations h-index g-index papers 13 13 13 94 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Clinical Applications of Mesenchymal Stem/Stromal Cell Derived Extracellular Vesicles: Therapeutic Potential of an Acellular Product. Diagnostics, 2020, 10, 999.	2.6	34
2	Kinetic and Angiogenic Activity of Circulating Endothelial Colony Forming Cells in Patients with Infantile Haemangioma Receiving Propranolol. Thrombosis and Haemostasis, 2019, 119, 274-284.	3.4	7
3	Plasma sIL- $2R\hat{1}\pm$ levels are associated with disease progression in myelofibrosis with JAK2V617F but not CALR mutation. Leukemia Research, 2020, 90, 106319.	0.8	7
4	Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis. Leukemia, 2021, 35, 468-475.	7.2	7
5	Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm. Acta Haematologica, 2022, 145, 30-37.	1.4	7
6	Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes. Genes, 2021, 12, 1271.	2.4	4
7	Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. PLoS ONE, 2019, 14, e0220189.	2.5	3
8	Primary myelofibrosis: rs2010963 VEGFA polymorphism favors a prefibrotic phenotype and is associated with higher risk of thrombosis. Leukemia Research, 2021, 111, 106730.	0.8	3
9	VEGFA rs3025020 Polymorphism Contributes to CALR-Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis. TH Open, 2021, 05, e513-e520.	1.4	1
10	Bone Marrow Microenvironment in Light-Chain Amyloidosis: In Vitro Expansion and Characterization of Mesenchymal Stromal Cells. Biomedicines, 2021, 9, 1523.	3.2	0
11	Possible Role of Impaired Erk1,2 Phosphorilation and Increased sIL2r Alpha Plasma Levels in the Reduced Frequency of Circulating T Regulatory Cells of Patients with Primary Myelofibrosis. Blood, 2015, 126, 1639-1639.	1.4	0
12	Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity. Blood, 2018, 132, 4337-4337.	1.4	0
13	Elevated Plasma sIL-2Rα Levels in Primary Myelofibrosis Play a Distinct Role on Disease Progression in JAK2V617F and Calr Mutants. Blood, 2019, 134, 1678-1678.	1.4	O